1. United States Stocks

  2. •

    Technology services

  3. •

    Packaged software
Cellev8 Nutrition Inc.

Cellev8 Nutrition Inc.

OOTC:CELV
0.15
USD
+0.01
(+3.57%)
-0.02EPS
8.45MMarket Cap
Cellev8 Nutrition Inc.
OTC:CELV
(OTC Markets)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2014
2015
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.2
-1.16
-1.28
-0.96
-0.04
-0.03
-0.01
Basic EPS, GAAP
- -
-0.12
-0.7
-1.72
-0.06
-0.02
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-3.33
-0.88
-2.41
-3.44
-0.14
-0.17
-0.14
Book Value per Share
- -
-3.33
-0.88
-2.41
-3.44
-0.14
-0.17
-0.14
Tangible Book Value per Share
- -
- -
- -
- -
- -
53
55
66
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-2,012.06
-628.08
-674.18
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
-2
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-2,251.83
-734.3
-326.75
Profit Margin (%)
- -
- -
- -
- -
- -
-8
-9
-10
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
-8
-9
-10
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Aug'16
Feb'16
May'16
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
70
70
Market Capitalization
- -
12
8

Working Capital

USD

•

in mil. unless spec.
Aug'16
Feb'16
May'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
10
11
Payables & Accruals
5
6
6
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
421.07%
24.14%
Free Cash Flow
- -
3,984.49%
-38.98%
Net Income, GAAP
- -
380.07%
-10.97%
Sales/Revenue/Turnover
- -
- -
173.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
Cellev8 Nutrition Inc (OTC: CELV), formerly Preferred Commerce Inc, develops, markets and sells proprietary Superoxide Dismutase (SOD)-based nutraceutical supplements in gummy form designed to support cellular health, reduce oxidative stress, inflammation and promote recovery, focus and memory; core products include Inflammation & Recovery Gummies featuring tart cherry extract, red orange complex and pomegranate extract; Focus & Memory Gummies; and GLP1 Support Gummies branded SlimCell with clinically proven ingredients to complement GLP-1 therapies. The company operates in the health and wellness sector targeting athletes, professional and collegiate sports teams, active individuals and general consumers seeking antioxidant support for mitochondrial function, nutrient absorption and overall vitality; it serves thousands of customers including over 40 professional and collegiate athletic teams across the United States. Founded in 1999 and headquartered in Wellington, Florida, Cellev8 Nutrition employs patent-pending delivery systems to enhance bioavailability of SOD combined with antioxidants and soluble corn fiber. Recent developments include the filing of two patents at the US Trademark and Patent Office in December 2024 for advanced ingredient delivery mechanisms applicable to its product range; the launch of its first GLP1 Support Gummy in late 2024; a November 2024 shareholder update clarifying its focus on SOD innovation and retracting prior CBD/cannabis intentions from 2019-2020; and a partnership with NFL legend Andre Reed announced to promote cellular health products in sports.